recAP

BIOLOGICAL2 trials

Sponsors

AM-Pharma, Maire Gilmartin

Conditions

Acute Kidney InjuryCritical Illness

Phase 2

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

CompletedNCT02182440

AM-PharmaAcute Kidney Injury

Start: 2014-12-18End: 2017-09-27Updated: 2020-03-23

Unknown Phase

REhabilitation After Critical Illness Assisted Discharge Pack (RECAP)

CompletedNCT02415634

Maire GilmartinCritical Illness

Start: 2014-11-30End: 2015-07-31Updated: 2015-11-17

Related Papers

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

JAMA2018-10-25169 citations

Study protocol for a multicentre randomised controlled trial: <i>S</i> afety, <i>T</i> olerability, efficacy and quality of life <i>O</i> f a human recombinant alkaline <i>P</i> hosphatase in patients with sepsis-associated <i>A</i> cute <i>K</i> idney <i>I</i> njury (STOP-AKI)

BMJ Open2016-09-0137 citations